Economic evaluations in high-income countries have found that this use of trastuzumab generally provides value for money; however, its cost-effectiveness for specific subtypes of HER2+ breast cancer (defined by estrogen receptor [ER] and progesterone receptor [PR] status) is unknown. The gene discussed is ESR1; the disease is breast cancer.